РЕЗЮМЕ
Избыточный бактериальный рост в тонком кишечнике (SIBO) представляет собой отдельную, но взаимосвязанную форму дисбиоза кишечника и часто сосуществует с более широкими изменениями в разнообразии кишечной микробиоты, особенно у пациентов с хроническими заболеваниями печени. Чрезмерная колонизация тонкого кишечника патогенными или условно-патогенными бактериями, способствует повышению кишечной проницаемости, эндотоксемии и системному воспалению, что усугубляет поражение печени. Кишечник и печень тесно взаимосвязаны, и нарушения в составе кишечной микробиоты могут оказывать существенное влияние на здоровье печени (ось «кишечник–печень»). В данном обзоре авторы осветили все основные механизмы повреждения печени при SİBO и факторы риска, связанные с данным состоянием, влияющие на тяжесть клинического течения вирусных гепатитов.
Keywords: синдром избыточноо бактериального роста, хронические заболевания печени, вирусные гепатиты, фиброз печения, методы диагностики

---

ЛИТЕРАТУРА

1. Cani P: Human gut microbiome: Hopes, threats and promises // Gut, 2018 Sep;67(9):1716-1725. doi: 10.1136/gutjnl-2018-316723.
2. Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J. et al. The cirrhosis dysbiosis ratio defines changes in the gut microbiome associated with cirrhosis and its complications // J. Hepatol., 2014;60, 940-947. doi: 10.1016/j.jhep.2013. 12.019.
3. Hills Rd Jr, Pontefract BA, Mishcon HR, Black cA, Sutton S and Theberge cR: Gut microbiome: Profound implications for diet and disease // Nutrients, 2019;11(7):1613. doi: 10.3390/nu11071613.
4. Bolte LA, Vich Vila A, Imhann F, Collij V. et al: Long‑term dietary patterns are associated with pro‑inflammatory and anti‑inflammatory features of the gut microbiome // Gut, 2021;70(7):1287-1298. doi: 10.1136/gutjnl-2020-322670.
5. Odamaki T, Kato K, Sugahara H. et al. Age‑related changes in gut microbiota composition from newborn to centenarian: A cross‑sectional study // BMc Microbiol., 2016. 16: 90. doi:10.1186/s12866-016-0708-5.
6. Wang, W.-W., Zhang, Y., Huang, X.-B. et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction // World J. Gastroenterol. 2017; 23: 6983. doi: 10.3748/wjg.v23.i38.6983.
7. Giannelli V, Di Gregorio V, Iebba V. et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis // World J Gastroenterol., 2014; 20(45):16795-16810. doi: 10.3748/wjg.v20.i45.16795.
8. Milosevic I, Vujovic A, Barac A, Djelic M, Korac M. et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature // Int J Mol Sci., 2019;20(2):395. doi: 10.3390/ijms20020395.
9. Grąt M, Wronka KM, Krasnodębski M. et al. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis // Transplant Proc., 2016;48(5):1687-91. doi: 10.1016/j.transproceed.2016.01.077.
10. Zindel J and Kubes P: dAMPs, PAMPs, and LAMPs in immunity and sterile inflammation // Annu Rev Pathol., 2020:15:493-518. doi: 10.1146/annurev-pathmechdis-012419-032847.
11. Puche JE, Saiman Y., Friedman S.L: Hepatic stellate cells and liver fibrosis // Compr Physiol., 2013;3(4):1473-92. doi: 10.1002/cphy.c120035.
12. Barry AE, Baldeosingh R, Lamm R, Patel K. et al. Hepatic stellate cells and hepatocarcinogenesis // Front Cell Dev Biol., 2020;8:709. doi: 10.3389/fcell.2020.00709.
13. Ju c and Tacke F: Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies // Cell Mol Immunol., 2016;13(3):316-27. doi: 10.1038/cmi.2015.104.
14. Mohamadkhani, A. On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B // Cancer Med., 2018;7, 3095-3100. doi: 10.1002/cam 4.1550.
15. Bajaj, J. S., Kassam, Z., Fagan, A., Gavis, E. A., Liu, E., Cox, I. J., et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial // Hepatology, 2017; 66, 1727-1738. doi: 10.1002/hep.29306.
16. Visvanathan K., Skinner N. A., Thompson A.J. et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precure protein // Hepatology, 2007; 45, 102-110. doi: 10.1002/hep.21482.
17. Inoue T, Nakayama J, Moriya K, Kawaratani H, et al: Gut dysbiosis associated with hepatitis c virus infection. clin Infect dis // Clin Infect Dis., 2018;67(6):869-877. doi: 10.1093/cid/ciy205.
18. Ponziani, F.R., Putignani L., Paroni Sterbini F. et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis // Aliment. Pharmacol. Ther., 2018; 48, 1301-1311. doi: 10.1111/apt.15004.
19. Pérez-Matute, P., Íñiguez, M., Villanueva-Millán, M. J. et al. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients // Eur. J. Inter. Med., 2019; 67, 47-58. doi: 10.1016/j.ejim.2019.06.005.
20. Dixon L.J., Barnes M., Tang H., Pritchard, M. T., Nagy, L.E. Kupffer cells in the liver // Compr. Physiol., 2013; 3, 785-797. doi: 10.1002/cphy.c120026.
21. Mencin, A., Kluwe, J., and Schwabe, R. F. Toll-like receptors as targets in chronic liver diseases // Gut, 2009; 58, 704-720. doi: 10.1136/gut.2008.156307.
22. Batsis Id, Wasuwanich P., Karnsakul WW: The management of hepatitis B and hepatitis c in children // Minerva Pediatr, 2019; Vol.71:59‑75. doi: 10.23736/S0026-4946.18.05410-5.
23. Visvanathan, K., Skinner, N. A., Thompson, A. J. et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein // Hepatology, 2007; 45, 102-110. doi: 10.1002/hep.21482.
24. Wei X, Yan X, Zou d, Yang Z. et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach // BMC Gastroenterol., 2013; 26:13:175. doi: 10.1186/1471-230X-13-175.
25. Zeng Y, c hen S, Fu Y, Wu W, c hen T, c hen J, Yang B and Ou Q: Gut microbiota dysbiosis in patients with hepatitis B virus‑induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma // J Viral Hepat., 2020;27(2):143-155. doi: 10.1111/jvh. 13216.
26. Liu, Q., Li, F., Zhuang, Y., Xu, J. et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma // Gut Pathog., 2019; 11:11. doi: 10.1186/s13099-018-0281-6.
27. Zhao, Y., Mao, Y. F., Tang, Y.S., Ni M.Z. et al. Altered oral microbiota in chronic hepatitis B patients with different tongue coatings // World J. Gastroenterol., 2018; 24:3448. doi: 10.3748/wjg.v24.i30.3448.
28. Yun Y, Chang Y, Kim HN, Ryu S. et al. Alterations of the Gut Microbiome in Chronic Hepatitis B Virus Infection Associated with Alanine Aminotransferase Level // J Clin Med., 2019; 8: 173. doi: 10.3390/jcm8020173.
29. Voukelatou P, Vrettos I, Kalliakmanis A. Neurologic symptoms as the only manifestation of B12 deficiency in a young patient with normal hematocrit, MCV, peripheral blood smear and homocysteine levels // Oxf Med Case Reports., 2016; omw091 [PMID: 28031855 doi:10.1093/omcr/omw091.
30. Cui L, Morris A, Ghedin E. The human mycobiome in health and disease // Genome Med 2013; 5: 63. PMID: 23899327. doi: 10.1186/gm467.
31. Tang, G., Yin, W., and Liu, W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? // Diagn. Microbiol. Infect. Dis. 2017; 88, 322-329. doi: 10.1016/j.diagmicrobio.2017.05.007.
32. Woodhouse, C. A., Patel, V. C., Goldenberg, S., Sanchez-Fueyo, A., China, L., O’Brien, A., et al. PROFIT, a prospective, randomised placebo-controlled feasibility trial of faecal microbiota transplantation in cirrhosis: study protocol for a single-blinded trial // BMJ 2019; 9:e023518. doi: 10.1136/bmjopen-2018-023518.
33. Meiglani, A., Alimirah, M., Ramesh, M., and Salgia, R. Fecal microbiota transplantation for Clostriodioides difficile infection in patients with chronic liver disease // Int. J. Hepatol. 2020:1874570. doi: 10.1155/2020/1874570.